GHRP-1 vs IGF-1 LR3.

GHRP-1 is a synthetic heptapeptide, one of the earliest growth hormone-releasing peptides (GHRPs) developed by Cyril Bowers' group in the 1980s and 1990s alongside GHRP-2 and GHRP-6. It is a growth hormone secretagogue, meaning it prompts the pituitary to release the body's own GH rather than being a form of GH itself. It predates the discovery of ghrelin and was one of the pharmacological tools that led researchers to the growth hormone secretagogue receptor (GHS-R1a). It has always been a research compound and was never developed into an approved drug.

IGF-1 LR3 (Long R3 IGF-1) is a synthetic, recombinant analog of human insulin-like growth factor-1. It is an 83-amino-acid polypeptide built from the 70-residue native IGF-1 sequence with two structural changes: a glutamate-to-arginine substitution at position 3 and a 13-residue N-terminal extension peptide. It is produced and sold primarily as a research reagent and as a cell-culture supplement (marketed under names such as LONG R3 IGF-I), not as a licensed human medicine.

GHRP-1 acts as an agonist at GHS-R1a, the receptor later identified as the endogenous ghrelin receptor, which is expressed in the pituitary and hypothalamus. This is a pathway distinct from growth hormone-releasing hormone (GHRH); GHRPs raise GH through a dual action on somatotrophs and on hypothalamic somatostatin and GHRH tone. Because GHRPs were synthesized before ghrelin was identified in 1999, they are best understood as synthetic ghrelin-mimetic secretagogues. The acute receptor mechanism is well characterized in animals and in short human pituitary-response studies.

Like native IGF-1, LR3 binds and activates the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase that signals through the PI3K/Akt/mTOR and Ras/MAPK pathways to drive protein synthesis, cell proliferation, and survival. Its distinguishing feature is engineered: the position-3 arginine substitution plus the N-terminal extension dramatically lower its affinity for the six IGF-binding proteins (IGFBPs) that normally sequester circulating IGF-1. Because little of the analog is bound and held by IGFBPs, a much larger fraction remains free to engage IGF-1R, and in animal models its circulating half-life is substantially longer than that of native IGF-1. This same "escape from IGFBP regulation" is why it is favored in mammalian cell culture, where it resists sequestration by cell-secreted binding proteins.

The GH-releasing activity of GHRP-1 in humans was documented early. Laron, Bowers and colleagues reported in Acta Endocrinologica (1993, PMID 8279223) that intravenous GHRP-1 produced dose-related rises in plasma GH in children and adolescents. That study was an acute endocrine-challenge design: small numbers of participants, single administrations, GH sampled over a few hours, no placebo comparison and no blinding, and no follow-up beyond the sampling window. It answers one question, whether the pituitary responds, and no others. Bowers' wider body of work defined the GHRP class and its combined pituitary and hypothalamic actions, showing that GHRPs act through a receptor separate from the GHRH receptor and that the two stimuli are synergistic when given together. Those experiments formed the pharmacological trail that led to the cloning of GHS-R1a and then to the identification of ghrelin as its natural ligand in 1999 (PMID 10604470). GHRP-1 specifically has far less human data than its siblings GHRP-2 and GHRP-6, and most of its literature consists of acute endocrine-response and animal experiments. GHRP-2 and GHRP-6 accumulated repeat-administration studies, diagnostic use in the assessment of GH deficiency, and observations on appetite and body composition. Ipamorelin, developed later in the same class, was characterized as a more selective secretagogue that raises GH with less accompanying cortisol and prolactin release (PMID 9849822). Nothing comparable exists for GHRP-1, which was largely bypassed once its siblings and then ghrelin itself became the preferred research tools. What is not known is most of it. There are no controlled trials of chronic GHRP-1 use, body composition, or clinical outcomes. There is no published human pharmacokinetic profile for the compound as it is sold, no bioavailability data for routes other than the intravenous administration used in the original studies, no dose-response work extending past the acute GH peak, and no evidence on whether pituitary responsiveness is sustained or subject to tachyphylaxis with repeated exposure. The evidence amounts to proof of mechanism rather than proof of benefit.

Direct evidence for LR3 is overwhelmingly preclinical and in-vitro, not clinical. In a guinea pig study (Conlon et al., J Endocrinol 1995, PMID 7561636), Long R3 IGF-I infusion stimulated organ growth while paradoxically lowering plasma IGF-I, IGF-II, and IGFBP concentrations, illustrating its altered binding-protein behavior in vivo. A mouse study (J Endocrinol 2008, PMID 18577570) reported that long-R3-IGF-I altered mammary signaling and gene expression during prolonged lactation. Analytical work (J Chromatogr B 2003, PMID 12880859) characterized the molecule for bioanalytical detection. There are no controlled human trials demonstrating safety or performance/physique benefits for IGF-1 LR3 specifically; clinical inferences are extrapolated from native IGF-1 (mecasermin) and from receptor pharmacology, which is a meaningful gap because LR3's reduced IGFBP binding changes its tissue exposure relative to the natural hormone.

Acute administration in the early studies was generally tolerated, but there is no long-term human safety data for GHRP-1. As a GH secretagogue it carries the same theoretical concerns as sustained GH elevation, including insulin resistance and fluid retention, and some GHRPs also raise cortisol and prolactin. Those class effects are documented rather than hypothetical: GHRP-2 and GHRP-6 both stimulate ACTH and cortisol release to a degree that ipamorelin was specifically engineered to avoid, and GHRP-6 is a strong appetite stimulant acting through the same ghrelin receptor. Where GHRP-1 sits on that spectrum has never been mapped in a dedicated human study. The recognized consequences of prolonged growth hormone excess, drawn from acromegaly and from supraphysiological GH use, include carpal tunnel symptoms, arthralgia, peripheral edema, worsened glucose tolerance, and cardiac hypertrophy. None of these have been studied for GHRP-1, because no chronic exposure trial exists. Formal toxicology and carcinogenicity packages for the compound are not present in the public literature, and immunogenicity has not been assessed. A legitimate trial would require serial IGF-1 measurement, fasting glucose and insulin or an oral glucose tolerance test, cortisol and prolactin monitoring, thyroid function testing, and periodic assessment for fluid retention and joint symptoms. None of that monitoring occurs outside a clinical setting. Product sold online as GHRP-1 is unregulated research-grade material of uncertain identity and purity, so a vial may contain a different secretagogue, a degraded or truncated peptide, or residual endotoxin and synthesis solvents, and independent testing of the grey peptide market has repeatedly found mislabeled contents. Its human safety profile is largely uncharacterized.

No human safety dataset exists for IGF-1 LR3 itself; the closest human reference is the FDA-approved native IGF-1 drug mecasermin (Increlex), whose label documents hypoglycemia (including severe, seizure-associated events from its insulin-like action), intracranial hypertension with papilledema, and lymphoid (tonsillar/adenoidal) tissue hypertrophy. Because IGF-1R signaling is mitogenic and anti-apoptotic, a theoretical concern across IGF-1 agonists is the promotion of growth in existing neoplastic tissue, though this has not been quantified for LR3 in humans. LR3's much longer free-ligand exposure could plausibly amplify these effects relative to native IGF-1, but this is unverified. Research-grade material also carries purity, sterility, and mislabeling risks that are not controlled to pharmaceutical standards.

GHRP-1 has never been approved by the FDA or any major regulator for any indication. It is a research chemical sold only for laboratory use. As a growth hormone secretagogue it is prohibited in sport by WADA.

IGF-1 LR3 is not approved by the FDA or any major regulator for human use; it is sold for laboratory research and cell-culture manufacturing only. The only FDA-approved IGF-1 product is mecasermin (Increlex), recombinant native IGF-1 indicated for severe primary IGF-1 deficiency, which is a different molecule. IGF-1 and its analogues are prohibited in sport at all times under WADA Prohibited List section S2.